TITLE

A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia

AUTHOR(S)
Caccia, Silvio; Invernizzi, Roberto William; Nobili, Alessandro; Pasina, Luca
PUB. DATE
August 2013
SOURCE
Therapeutics & Clinical Risk Management;2013, Vol. 9, p319
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Cariprazine is a potential antipsychotic awaiting approval from the US Food and Drug Administration. It is a dopamine D2- and D3-receptor partial agonist, with higher affinity for D3 receptors, as opposed to the D2 antagonism of most older antipsychotic agents. Like most lipophilic antipsychotics, it undergoes extensive hepatic metabolism by cytochrome P450 (CYP), mainly the highly variable 3A4, with the formation of active metabolites. However, the parent compound - particularly its active didesmethyl derivative - is cleared very slowly, with elimination half-lives in schizophrenic patients ranging from 2-5 days for cariprazine to 2-3 weeks for didesmethyl-cariprazine. Exposure to the latter was several times that for cariprazine, although didesmethyl-cariprazine did not reach steady state within the 3 weeks of 12.5 mg/day dosing. Preliminary information on its therapeutic role comes from press releases and a few abstracts presented at scientific meetings. In short-term controlled trials, it was more effective than placebo in reducing positive and negative symptoms of schizophrenia, with an effective dose range of 1.5-12 mg/day. Although cariprazine was associated with a higher incidence of akathisia and extrapyramidal side effects than placebo, it did not cause weight gain, metabolic abnormalities, prolactin increase, or corrected QT prolongation. Similarly, cariprazine's efficacy and tolerability for the treatment of bipolar disorder (manic/mixed and depressive episodes) was established in the dose range of 3-12 mg/day, although again no long-term data are available. Well-designed clinical trials, mainly direct "head-to-head" comparisons with other second-generation antipsychotic agents, are needed to define the therapeutic role and safety profile of cariprazine in schizophrenia and bipolar mania.
ACCESSION #
90019707

 

Related Articles

  • Monthly Consta Kaput; Alkermes, J&J Face Sustenna. Hollingsworth, Catherine // BioWorld Today;8/28/2009, Vol. 20 Issue 166, p1 

    The article reports that partners Janssen LP and Alkermes Inc. have decide not to push through with plans to formulate a once-monthly version of Risperdal Consta, an antipsychotic drug. The current form of the drug is delivered by injection and is used by patients with bipolar disorder and...

  • Risperdal Consta update.  // MPR - Residents' Edition;Fall/Winter2009, Vol. 18 Issue 2, pA7 

    The article reports on the approval of the new monotherapy or adjuvant therapy Risperdal Consta from Janssen Pharmaceutica NV in the maintenance treatment of bipolar I disorder by the U.S. Food and Drug Administration (FDA). It mentions that the drug is a risperidone long-acting injection and it...

  • FDA Actions. Elliott, William T. // Clinical Cardiology Alert;Nov2009 Pharmacology Watch, p2 

    This section offers news briefs concerning the Food and Drug Administration (FDA) in the U.S. Asenapine has been given approval by the FDA as cure for schizophrenia and bipolar I disorder in adults. The FDA also reduced the approved age limit for levocetirizine to 6 months for children suffering...

  • FDA Actions. Elliott, William T. // Neurology Alert;Nov2009 Pharmacology Watch, p2 

    This section offers news briefs concerning the Food and Drug Administration (FDA) in the U.S. Asenapine has been given approval by the FDA as cure for schizophrenia and bipolar I disorder in adults. The FDA also reduced the approved age limit for levocetirizine to 6 months for children suffering...

  • FDA Actions. Elliott, William T. // Primary Care Reports;Nov2009 Pharmacology Watch, p2 

    The article presents updates about the drug approval decisions of the U.S. Food and Drug Administration (FDA). Asenaphine has been approved for treating schizophrenia and bipolar I disorder in adults. This is expected to carry a warning regarding increased mortality in elderly patients with...

  • FDA Actions. Elliott, William T. // Clinical Oncology Alert;Nov2009 Supplement, p2 

    This section offers news briefs concerning the Food and Drug Administration (FDA) in the U.S. Asenapine has been given approval by the FDA as cure for schizophrenia and bipolar I disorder in adults. The FDA also reduced the approved age limit for levocetirizine to 6 months for children suffering...

  • FDA Issues CRL for Alexza Pharmaceuticals' Adasuve. Shaffer, Catherine // BioWorld Today;5/7/2012, Vol. 23 Issue 88, p1 

    This article reports on the decision of the U.S. Food and Drug Administration (FDA) to issue a complete response letter for Alexza Pharmaceuticals Inc.'s Adasuve inhalation powder for agitation in schizophrenia and bipolar disorder. According to the company, the agency cited manufacturing...

  • Sunovion: Latuda poised to expand options in bipolar depression.  // PharmaWatch: CNS;Dec2012, Vol. 11 Issue 12, p14 

    The article reports on the plan of Sunovion to expand options for the drug Latuda for depressive episodes in bipolar disorder. It cited the decision of the U.S. Food and Drug Administration (FDA) to review two supplemental New Drug Applications (sNDAs) for use of the drug as monotherapy and...

  • Fanapt.  // Pharmaceutical Representative;Jul2009, Vol. 39 Issue 7, p11 

    The article reports on the U.S. Food and Drug Administration's (FDA's) approval of Fanapt (Iloperidone) from Vanda Pharmaceuticals Inc. to treat schizophrenia. It notes that the drug was first developed by Hoechst and licensed to Titan Pharmaceuticals. The company plans to make the drug...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics